English
全部
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
搜索
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
5 天
Uplizna在重症肌无力临床试验中显示持续疗效
UPLIZNA已获批用于治疗抗水通道蛋白4(AQP4)抗体阳性的视神经脊髓炎谱系疾病(NMOSD)成年患者,目前正在接受FDA优先审查用于免疫球蛋白G4相关疾病(IgG4-RD)。该药物已获得gMG治疗的孤儿药资格认定,预计将在2025年上半年完成监管申报。目前交易价格为312.50美元, InvestingPro 分析表明Amgen目前估值合理。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Trans troops ban blocked
Return to Earth
Agrees to limited ceasefire
Delta plane wing hits runway
Removing privacy setting
Factory production rises
Judge on USAID shutdown
OH trans care ban blocked
Patient dies post-therapy
Siemens to cut jobs
Tesla vehicles set on fire
Retires after 15 seasons
Drops gun violence advisory
Morgan says he’s OK
Frozen meals recalled
Free checked bag promotion
'Sunrise on the Reaping'
Worker stole $1.6 million
Woman charged w/ murder
Texas measles cases rise
Earthquake shakes Bay Area
JFK files released
To open headquarters in TX
Honduras plane crash
Corruption trial begins
US housing starts rebound
On judicial impeachment call
Parents on missing daughter
'Get Together' singer dies
Reinstating fired workers
反馈